SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-110006"
 

Search: onr:"swepub:oai:DiVA.org:umu-110006" > Effect of Nateglini...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Holman, Rury R. (author)

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • 2010
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-110006
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-110006URI
  • https://doi.org/10.1056/NEJMoa1001122DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Correction: N Engl J Med 2010; 362:1748 May 6, 2010 DOI: 10.1056/NEJMx100020
  • BACKGROUND The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. METHODS In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization. RESULTS After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P = 0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P = 0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P = 0.16). Nateglinide did, however, increase the risk of hypoglycemia. CONCLUSIONS Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes. (ClinicalTrials.gov number, NCT00097786.)

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Haffner, Steven M. (author)
  • McMurray, John J. (author)
  • Bethel, M. Angelyn (author)
  • Holzhauer, Bjoern (author)
  • Hua, Tsushung A. (author)
  • Belenkov, Yuri (author)
  • Boolell, Mitradev (author)
  • Buse, John B. (author)
  • Buckley, Brendan M. (author)
  • Chacra, Antonio R. (author)
  • Chiang, Fu-Tien (author)
  • Charbonnel, Bernard (author)
  • Chow, Chun-Chung (author)
  • Davies, Melanie J. (author)
  • Deedwania, Prakash (author)
  • Diem, Peter (author)
  • Einhorn, Daniel (author)
  • Fonseca, Vivian (author)
  • Fulcher, Gregory R. (author)
  • Gaciong, Zbigniew (author)
  • Gaztambide, Sonia (author)
  • Giles, Thomas (author)
  • Horton, Edward (author)
  • Ilkova, Hasan (author)
  • Jenssen, Trond (author)
  • Kahn, Steven E. (author)
  • Krum, Henry (author)
  • Laakso, Markku (author)
  • Leiter, Lawrence A. (author)
  • Levitt, Naomi S. (author)
  • Mareev, Viacheslav (author)
  • Martinez, Felipe (author)
  • Masson, Chantal (author)
  • Mazzone, Theodore (author)
  • Meaney, Eduardo (author)
  • Nesto, Richard (author)
  • Pan, Changyu (author)
  • Prager, Rudolf (author)
  • Raptis, Sotirios A. (author)
  • Rutten, Guy E. H. M. (author)
  • Sandström, HerbertUmeå universitet,Allmänmedicin(Swepub:umu)hesa0015 (author)
  • Schaper, Frank (author)
  • Scheen, Andre (author)
  • Schmitz, Ole (author)
  • Sinay, Isaac (author)
  • Soska, Vladimir (author)
  • Stender, Steen (author)
  • Tamas, Gyula (author)
  • Tognoni, Gianni (author)
  • Tuomilehto, Jaako (author)
  • Villamil, Alberto S. (author)
  • Vozar, Juraj (author)
  • Califf, Robert M. (author)
  • Umeå universitetAllmänmedicin (creator_code:org_t)

Related titles

  • In:New England Journal of Medicine362:16, s. 1463-14760028-47931533-4406

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view